摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-己基癸酰氯 | 74918-57-3

中文名称
2-己基癸酰氯
中文别名
异棕榈酰氯
英文名称
2-hexyldecanoyl chloride
英文别名
2-hexyldecanoic acid chloride
2-己基癸酰氯化学式
CAS
74918-57-3
化学式
C16H31ClO
mdl
——
分子量
274.875
InChiKey
MHEDPJJXDOOCQO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    326.9±10.0 °C(Predicted)
  • 密度:
    0.911±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    7.9
  • 重原子数:
    18
  • 可旋转键数:
    13
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.94
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2915900090

SDS

SDS:a0fac5bf6df8055f374b31c2cb112e3b
查看

反应信息

  • 作为反应物:
    描述:
    2-己基癸酰氯ammonium hydroxide 作用下, 以 二氯甲烷 为溶剂, 以22 g的产率得到2-hexyldecanoyl amide
    参考文献:
    名称:
    [EN] LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE
    [FR] ADMINISTRATION LIPIDIQUE D'AGENTS THÉRAPEUTIQUES AU TISSU ADIPEUX
    摘要:
    本发明提供了一种治疗由脂肪组织中蛋白质表达介导的疾病的方法,通过腹膜内给药一种包含脂质纳米粒的制剂,该脂质纳米粒封装或与治疗剂(例如,核酸)相关联,从而将治疗剂递送到受试者的脂肪组织并改变脂肪组织中的蛋白质表达。本发明还提供了一种将治疗剂递送到需要治疗的受试者脂肪组织的方法。
    公开号:
    WO2018191719A1
  • 作为产物:
    描述:
    2-正己基癸酸草酰氯 作用下, 以 二氯甲烷 为溶剂, 反应 9.0h, 生成 2-己基癸酰氯
    参考文献:
    名称:
    Mild methods to assemble and pattern organic monolayers on hydrogen-terminated Si(111)
    摘要:
    本文报告了采用2,2,6,6-四甲基-1-哌啶氧自由基的温和方法,在Si(111)上组装有序的烯烃单分子层,并利用软光刻技术在微米尺寸尺度上对这些单分子层进行图案化。
    DOI:
    10.1039/b503271g
点击查看最新优质反应信息

文献信息

  • Bna Conjugates and Methods of Use
    申请人:James Kenneth D.
    公开号:US20080207505A1
    公开(公告)日:2008-08-28
    Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, decreasing arterial blood pressure and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the hBNP compound are also disclosed, having an amino acid sequence that is other than the native sequence.
    本发明公开了改性利钠肽化合物及其共轭物。具体而言,提供了至少连接有一个修饰基团的hBNP的共轭形式。这些改性利钠肽化合物共轭物保留了刺激cGMP产生、结合NPR-A受体、降低动脉血压以及在某些实施例中相对于未经改性的对应利钠肽化合物具有改善的循环半衰期的活性。这些化合物和共轭物的口服、静脉注射、肠内、皮下、肺部和静脉形式可作为治疗和/或治疗心脏病症,特别是充血性心力衰竭的治疗。还公开了包含具有各种长度和构型的寡聚结构的修饰基团。此外,还公开了hBNP化合物的类似物,其氨基酸序列与天然序列不同。
  • [EN] DELIVERY OF TARGET SPECIFIC NUCLEASES<br/>[FR] ADMINISTRATION DE NUCLÉASES SPÉCIFIQUES À UNE CIBLE
    申请人:SANGAMO THERAPEUTICS INC
    公开号:WO2018107026A1
    公开(公告)日:2018-06-14
    Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.
    本发明描述了包含阳离子脂质和其他脂质的脂质纳米颗粒,以及包含工程核酸酶以促进核酸向细胞的转移。
  • [EN] LIPID NANOPARTICLE FORMULATIONS<br/>[FR] FORMULATIONS DE NANOPARTICULES LIPIDIQUES
    申请人:ACUITAS THERAPEUTICS INC
    公开号:WO2018081480A1
    公开(公告)日:2018-05-03
    Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.
    提供了改进的脂质纳米粒子配方。还提供了利用这些脂质纳米粒子传递治疗剂的方法以及它们的制备方法。
  • SKIN EXTERNAL PREPARATIONS AND COSMETICS
    申请人:Aoki Hirobumi
    公开号:US20100280111A1
    公开(公告)日:2010-11-04
    An object of the present invention is to provide skin external preparations and cosmetics which contain a branched acyl carnitine and have excellent formulation stability. A skin external preparation of the present invention includes a carnitine derivative represented by the following Formula (1) and/or a carnitine derivative salt represented by the following Formula (2), and an amphoteric surfactant. In Formula (1), R 1 and R 2 are each independently a C1-18 optionally branched, saturated or unsaturated aliphatic hydrocarbon group. In Formula (2), R 1 and R 2 are the same as in Formula (1), X − is a specific anion and Y + is a specific cation.
    本发明的一个目的是提供含有支链酰基肉碱并具有优异配方稳定性的皮肤外用制剂和化妆品。本发明的皮肤外用制剂包括以下式(1)所表示的肉碱衍生物和/或以下式(2)所表示的肉碱衍生物盐,以及一种两性表面活性剂。在式(1)中,R1和R2分别独立地是C1-18的可选支链、饱和或不饱和脂肪烃基。在式(2)中,R1和R2与式(1)中相同,X−是特定的阴离子,Y+是特定的阳离子。
  • OLIGONUCLEOTIDE WITH PROTECTED BASE
    申请人:Ajinomoto Co., Inc.
    公开号:US20130267697A1
    公开(公告)日:2013-10-10
    The present invention provides a protected nucleotide for elongation, which can be purified efficiently and in a high yield by a liquid-liquid extraction operation, and can achieve an oligonucleotide production method by a phosphoramidite method. It has been found that the above-mentioned problem can be solved by a particular oligonucleotide comprising a protected base and/or particular oligonucleotide protected by a branched chain-containing aromatic group at 3′-position.
    本发明提供了一种用于延长的受保护核苷酸,可以通过液-液萃取操作高效且高产地纯化,并且可以通过磷酰胺酯法实现寡核苷酸的生产方法。已发现上述问题可以通过包含受保护碱基和/或在3'-位置带有分支链含芳基的特定寡核苷酸来解决。
查看更多